Gut Microbial Metabolites Inosine Combined With PD-1/PD-L1 Inhibitor for Patients With Malignant Advanced Solid Tumors

NCT05809336 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

COMPLETED

Status

172

Enrollment

OTHER

Sponsor class

Conditions

Advanced Solid Tumor

Interventions

DRUG: Inosine 0.2g orally 3 times/day
DRUG: PD-1/PD-L1 inhibitor ,chemotherapy/targeting

Sponsor

Beijing Friendship Hospital